AZD7648   Click here for help

GtoPdb Ligand ID: 10601

Synonyms: AZD-7648 | compound 16 [PMID: 31851518]
PDB Ligand
Compound class: Synthetic organic
Comment: AZD7648 is a selective inhibitor of DNA-dependent protein kinase (DNA-PK) [1]. DNA-PK is responsible for recognising and repairing double-strand DNA breaks in damaged DNA, and is a cancer drug target. AZD7648 is orally bioavailable.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 104.16
Molecular weight 380.17
XLogP 0.4
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C
Isomeric SMILES Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C
InChI InChI=1S/C18H20N8O2/c1-11-7-15-20-10-21-25(15)9-13(11)22-17-19-8-14-16(23-17)26(18(27)24(14)2)12-3-5-28-6-4-12/h7-10,12H,3-6H2,1-2H3,(H,19,22,23)
No information available.
Summary of Clinical Use Click here for help
AZD7648 has been advanced to preliminary stage clinical trial (NCT03907969) as either a monotherapy or in combination with olaparib or doxorubicin, in patients with advanced solid malignancies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03907969 A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers Phase 1/Phase 2 Interventional AstraZeneca
Pharmacokinetics Click here for help
Metabolism of AZD7648 is mediated predominantly by CYP3A4 and CYP3A5 [1]. AZD7648 does not modulate activity of any CYP enzymes in vitro, so the risk of drug-drug interactions in this respect is considered to be low.